Cargando…

COVID-19 vaccination precipitating de novo ANCA-associated vasculitis: clinical implications

Detalles Bibliográficos
Autores principales:	Mai, Aaron Shengting, Tan, Eng-King
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050521/ https://www.ncbi.nlm.nih.gov/pubmed/35498903 http://dx.doi.org/10.1093/ckj/sfac026

Ejemplares similares

Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era
por: Sato, Tomohito, et al.
Publicado: (2023)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19
por: Uppal, Nupur N., et al.
Publicado: (2020)

De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021)

Membranous glomerulonephritis with superimposed ANCA-associated vasculitis: another case report
por: Granata, Antonio, et al.
Publicado: (2011)

Adapted treatment of ANCA-associated vasculitis during the COVID-19 pandemic
por: Nimmo, Ailish, et al.
Publicado: (2021)

Cardiovascular risk assessment in lupus nephritis and ANCA-associated vasculitis in real-world nephrology practice
por: Tan, Hui Zhuan, et al.
Publicado: (2022)

New-Onset ANCA-Associated Vasculitis in a Patient with SARS-COV2
por: Cobilinschi, Claudia, et al.
Publicado: (2021)

Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis
por: Sethi, Amit, et al.
Publicado: (2023)

ANCA Associated Vasculitis Subtypes: Response [Letter]
por: Merkel, Peter A, et al.
Publicado: (2022)

Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2
por: Irure-Ventura, Juan, et al.
Publicado: (2022)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
por: Wang, Choon Ying, et al.
Publicado: (2022)

COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab()
por: Baldallo, Cinthia, et al.
Publicado: (2021)

De novo IgA vasculitis following adenovirus-based SARS-CoV-2 vaccination
por: Oniszczuk, Julie, et al.
Publicado: (2021)

Early and late ANCA vasculitis relapses after kidney transplantation may have different presentations
por: Masset, Christophe, et al.
Publicado: (2022)

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
por: King, Catherine, et al.
Publicado: (2017)

Therapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage
por: Tripathi, Parmatma P, et al.
Publicado: (2021)

Rapid progression of atherosclerosis in a patient with acute coronary syndrome and ANCA-associated vasculitis: split or confluence?
por: LI, Ya-Chao, et al.
Publicado: (2022)

A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)

ANCA glomerulonephritis after the Moderna COVID-19 vaccination
por: Sekar, Arjun, et al.
Publicado: (2021)

ANCA Vasculitis Induction Management During the COVID-19 Pandemic
por: Salas, Antonio, et al.
Publicado: (2021)

The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023)

Circulating B Cells, Plasma Cells, and Treg Associate with ANCA Levels in ANCA-associated Vasculitis
por: Manrique, Joaquin, et al.
Publicado: (2020)

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
por: Austin, Keziah, et al.
Publicado: (2022)

Clinicopathologic Findings in Mass Forming ANCA-Associated Vasculitis
por: Gilani, Sarwat I., et al.
Publicado: (2022)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management
por: Ge, Shangqing, et al.
Publicado: (2022)

Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis
por: Zycinska, K, et al.
Publicado: (2009)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination
por: Gen, Shiko, et al.
Publicado: (2023)

Leukocytoclastic vasculitis and COVID-19 vaccination
por: Sookaromdee, P., et al.
Publicado: (2022)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine
por: Yadav, Rukesh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2t3f86jios7e5j06v2v3fj2d6g